EWA
TLX

EverSource Wealth Advisors’s Telix Pharmaceuticals TLX Stock Holding History

EverSource Wealth Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Sell
956
-876
-48% -$8.92K ﹤0.01% 2853
2026
Q1 		$17.5K Buy
1,832
+934
+104% +$7.12K ﹤0.01% 2585
2025
Q4 		$6.73K Buy
898
+773
+618% +$7.44K ﹤0.01% 2986
2025
Q3 		$1.2K Buy
125
+58
+87% +$711 ﹤0.01% 3708
2025
Q2 		$1.08K Sell
67
-70
-51% -$1.18K ﹤0.01% 3715
2025
Q1 		$2.3K Buy
+137
New +$2.39K ﹤0.01% 2862

Other funds holding TLX

Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

EverSource Wealth Advisors's TLX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Telix Pharmaceuticals (TLX) stake by 48% in Q2 2026, selling an estimated $8.92K and leaving 956 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2853.

EverSource Wealth Advisors first reported a position in TLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $17.5K in Q1 2026. 56 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • EverSource Wealth Advisors held 956 shares of Telix Pharmaceuticals worth $11K as of Q2 2026.
  • EverSource Wealth Advisors sold 876 Telix Pharmaceuticals shares in Q2 2026, an estimated $8.92K.
  • Telix Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2853 holding.
  • EverSource Wealth Advisors first reported a position in Telix Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • EverSource Wealth Advisors's Telix Pharmaceuticals position peaked at $17.5K in Q1 2026.
  • 56 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.